Tag: CPF

A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore | Taiwan News

Targeted therapy regimen, BRAFTOVI® (encorafenib) in combination with cetuximab, included on MOH Cancer Drug List, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer who have received prior systemic therapy. BRAFTOVI in combination with cetuximab has been included on MOH CDL, for patients with BRAFV600E-mutant metastatic colorectal cancer…

Continue Reading A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore | Taiwan News

Takeda Announces Topline Results of Phase 3 ADMIRECD II Trial of Alofisel darvadstrocel in Complex Crohns Perianal Fistulas

Osaka, Japan & Cambridge, Mass., United States:   Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission…

Continue Reading Takeda Announces Topline Results of Phase 3 ADMIRECD II Trial of Alofisel darvadstrocel in Complex Crohns Perianal Fistulas

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel in Complex Crohn’s Perianal Fistulas -October 18, 2023 at 09:35 am EDT

OSAKA – Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. The safety profile…

Continue Reading Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel in Complex Crohn’s Perianal Fistulas -October 18, 2023 at 09:35 am EDT

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study -October 17, 2023 at 07:30 pm EDT

Takeda Pharmaceutical Company Limited announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn?s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. The safety profile for darvadstrocel…

Continue Reading Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study -October 17, 2023 at 07:30 pm EDT

Takeda Pharmaceutical (TAK) Reports Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel

Takeda (NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. The safety profile for darvadstrocel…

Continue Reading Takeda Pharmaceutical (TAK) Reports Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel

Coupling between snoRNP assembly and 3′ processing controls box C/D snoRNA biosynthesis in yeast

journal contribution posted on 2004-06-16, 00:00 authored by M Morlando, M Ballarino, P Greco, E Caffarelli, Bernhard DichtlBernhard Dichtl, I Bozzoni RNA polymerase II transcribes genes encoding proteins and a large number of small stable RNAs. While pre-mRNA 3′-end formation requires a machinery ensuring tight coupling between cleavage and polyadenylation,…

Continue Reading Coupling between snoRNP assembly and 3′ processing controls box C/D snoRNA biosynthesis in yeast